+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cell Therapy Processing Market by Offering Type, and Application: Global Opportunity Analysis and Industry Forecast, 2019-2026

  • ID: 5031489
  • Report
  • March 2020
  • Region: Global
  • 186 Pages
  • Allied Analytics LLP

FEATURED COMPANIES

  • Cell Therapies Pty Ltd
  • Invitrx Inc.
  • Lonza Ltd
  • NantWorks LLC
  • Neurogeneration Inc.
  • Novartis AG
The global cell therapy processing market was valued at $1,695 million in 2018, and is projected to reach $12,062 million by 2026, registering a CAGR of 27.80% from 2019 to 2026.



Cell therapy is the administration of living cells to replace a missing cell type or to offer a continuous source of a necessary factor to achieve a truly meaningful therapeutic outcome. There are different forms of cell therapy, ranging from transplantation of cells derived from an individual patient or from another donor. The manufacturing process of cell therapy requires the use of different products such as cell lines and instruments. These cell therapies are used for the treatment of various diseases such as cardiovascular disease and neurological disorders.

Increase in the incidence of cardiovascular diseases, rise in the demand for chimeric antigen receptor (CAR) T cell therapy, increase in the R&D for the advancement in the research associated with cell therapy, increase in the potential of cell therapies in the treatment of diseases associated with lungs using stem cell therapies, and a rise in understanding of the role of stem cells in inducing development of functional lung cells from both embryonic stem cells (ESCs) & induced pluripotent stem (iPS) cells are the key factors that fuel the growth of the cell therapy processing market. Moreover, increase in a number of clinical studies relating to the development of cell therapy processing, a rise in the adoption of regenerative drug, introduction of novel technologies for cell therapy processing, increase in government investments for cell-based research, increase in number of GMP-certified production facilities, large number of oncology-oriented cell-based therapy clinical trials, and a rise in the development of allogeneic cell therapy are other factors that augment the growth of the market. However, high-costs associated with the cell therapies, and bottlenecks experienced by manufacturers during commercialization of cell therapies are expected to hinder the growth of the market.

The cell therapy processing market is segmented into offering type, application, and region. By type, the market is categorized into products, services, and software. The application covered in the segment include cardiovascular devices, bone repair, neurological disorders, skeletal muscle repair, cancer, and others. On the basis of region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, and rest of Asia-Pacific), and LAMEA (Latin America, Middle East, and Africa).

KEY BENEFITS FOR STAKEHOLDERS
  • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
  • A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

By Offering Type
  • Products
  • Services
  • Software

By Application
  • Cardiovascular Devices
  • Bone Repair
  • Neurological Disorders
  • Skeletal Muscle Repair
  • Cancer
  • Others

By Region
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Rest of Asia-Pacific
  • LAMEA
  • Latin America
  • Middle East
  • Africa

LIST OF KEY PLAYERS PROFILED IN THE REPORT
  • Cell Therapies Pty Ltd
  • Invitrx Inc.
  • Lonza Ltd
  • Merck & Co., Inc. (FloDesign Sonics)
  • NantWorks, LLC
  • Neurogeneration, Inc.
  • Novartis AG
  • Plasticell Ltd.
  • Regeneus Ltd
  • StemGenex, Inc.

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
  • Beckman Coulter, Inc.
  • Stemcell Technologies
  • MiltenyiBiotec GmbH
Frequently Asked Questions about the Global Cell Therapy Processing Market

What is the estimated value of the Global Cell Therapy Processing Market?

The Global Cell Therapy Processing Market was estimated to be valued at $1695.0 million in 2018.

What is the growth rate of the Global Cell Therapy Processing Market?

The growth rate of the Global Cell Therapy Processing Market is 27.8%, with an estimated value of $12062.0 million by 2026.

What is the forecasted size of the Global Cell Therapy Processing Market?

The Global Cell Therapy Processing Market is estimated to be worth $12062.0 million by 2026.

Who are the key companies in the Global Cell Therapy Processing Market?

Key companies in the Global Cell Therapy Processing Market include Cell Therapies Pty Ltd, Invitrx Inc., Lonza Ltd, Merck & Co. Inc. (FloDesign Sonics), NantWorks LLC, Neurogeneration Inc., Novartis AG, Plasticell Ltd. and StemGenex Inc.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Cell Therapies Pty Ltd
  • Invitrx Inc.
  • Lonza Ltd
  • NantWorks LLC
  • Neurogeneration Inc.
  • Novartis AG

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key Benefits for Stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Market player positioning, 2018
3.3. Porter’s five force analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in the incidence of cardiovascular diseases
3.4.1.2. Rise in the demand for chimeric antigen receptor (CAR) t cell therapy
3.4.1.3. Increase in the development of stem cell therapy approaches
3.4.2. Restraint
3.4.2.1. Poor demand in under developed countries
3.4.3. Opportunities
3.4.3.1. Growth opportunities in emerging markets
3.4.4. Impact analysis
CHAPTER 4: CELL THERAPY PROCESSING MARKET, BY OFFERING TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Products
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Services
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Software
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
CHAPTER 5: GLOBAL CELL THERAPY PROCESSING MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Cardiovascular diseases
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Bone Repair
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Neurological Disorders
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
5.5. Skeletal Muscle Repair
5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country
5.6. Cancer
5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by country
5.7. Other Applications
5.7.1. Market size and forecast, by region
5.7.2. Market analysis, by country
CHAPTER 6: CELL THERAPY PROCESSING MARKET, BY REGION
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends and opportunities
6.2.2. North America CELL THERAPY PROCESSING market, by country
6.2.2.1. U. S.
6.2.2.1.1. U. S. market size and forecast, by offering type
6.2.2.1.2. U. S. market size and forecast, by application
6.2.2.2. Canada
6.2.2.2.1. Canada market size and forecast, by OFFERING TYPE
6.2.2.2.2. Canada market size and forecast, by application
6.2.2.3. Mexico
6.2.2.3.1. Mexico market size and forecast, by OFFERING TYPE
6.2.2.3.2. Mexico market size and forecast, by application
6.2.3. North America market size and forecast, by offering type
6.2.4. North America market size and forecast, by application
6.3. Europe
6.3.1. Key market trends and opportunities
6.3.2. Europe cell therapy processing market, by country
6.3.2.1. Germany
6.3.2.1.1. Germany market size and forecast, by OFFERING TYPE
6.3.2.1.2. Germany market size and forecast, by application
6.3.2.2. France
6.3.2.2.1. France market size and forecast, by OFFERING TYPE
6.3.2.2.2. France market size and forecast, by application
6.3.2.3. UK
6.3.2.3.1. UK market size and forecast, by OFFERING TYPE
6.3.2.3.2. UK market size and forecast, by application
6.3.2.4. Italy
6.3.2.4.1. Italy market size and forecast, by OFFERING TYPE
6.3.2.4.2. Italy market size and forecast, by application
6.3.2.5. Spain
6.3.2.5.1. Spain market size and forecast, by OFFERING TYPE
6.3.2.5.2. Spain market size and forecast, by application
6.3.2.6. Rest of Europe
6.3.2.6.1. Rest of Europe market size and forecast, by OFFERING TYPE
6.3.2.6.2. Rest of Europe market size and forecast, by application
6.3.3. Europe market size and forecast, by OFFERING TYPE
6.3.4. Europe market size and forecast, by application
6.4. Asia-Pacific
6.4.1. Key market trends and opportunities
6.4.2. Asia-Pacific CELL THERAPY PROCESSING market, by country
6.4.2.1. Japan
6.4.2.1.1. Japan market size and forecast, by offering type
6.4.2.1.2. Japan market size and forecast, by application
6.4.2.2. China
6.4.2.2.1. China market size and forecast, by offering type
6.4.2.2.2. China market size and forecast, by application
6.4.2.3. India
6.4.2.3.1. India market size and forecast, by OFFERING TYPE
6.4.2.3.2. India market size and forecast, by application
6.4.2.4. Rest of Asia-Pacific
6.4.2.4.1. Rest of Asia-Pacific market size and forecast, by OFFERING TYPE
6.4.2.4.2. Rest of Asia-Pacific market size and forecast, by application
6.4.3. Asia-Pacific market size and forecast, by offering type
6.4.4. Asia-Pacific market size and forecast, by application
6.5. LAMEA
6.5.1. Key market trends and opportunities
6.5.2. LAMEA CELL THERAPY PROCESSING market, by country
6.5.2.1. Latin America
6.5.2.1.1. Latin America market size and forecast, by OFFERING TYPE
6.5.2.1.2. Latin America market size and forecast, by application
6.5.2.2. Middle East
6.5.2.2.1. Middle East market size and forecast, by OFFERING TYPE
6.5.2.2.2. Middle East market size and forecast, by application
6.5.2.3. Africa
6.5.2.3.1. Africa market size and forecast, by offering type
6.5.2.3.2. Africa market size and forecast, by application
6.5.3. LAMEA market size and forecast, by OFFERING TYPE
6.5.4. LAMEA market size and forecast, by application
CHAPTER 7: COMPANY PROFILES
7.1. Cell Therapies Pty Ltd
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.2. INVITRX INC.
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.3. LONZA LTD
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.4. Merck & Co. , Inc. (FloDesign Sonics)
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.5. NantWorks, LLC
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.6. Neurogeneration, Inc.
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.7. Novartis AG
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.8. Plasticell Ltd.
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Key strategic moves and developments
7.9. REGENEUS LTD
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.10. StemGenex, Inc.
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Cell Therapies Pty Ltd
  • Invitrx Inc.
  • Lonza Ltd
  • NantWorks LLC
  • Neurogeneration Inc.
  • Novartis AG
According to this report titled, 'Cell Therapy Processing Market by Offering Type, and Application: Global Opportunity Analysis and Industry Forecast, 2019-2026,' the cell therapy processing market size was valued at $1,695million in 2018, and is projected to reach $12,062million by 2026, growing at a CAGR of 27.8% from 2019 to 2026.

Cell therapy is the transplantation of human cells to replace or repair damaged tissue or cells. With new technologies, innovative products and limitless imagination, many different types of cells may be used as part of a therapy or treatment for a variety of diseases and conditions. Some of the cells that may be used include mesenchymal stem cells, dendritic cells, hematopoietic stem cells, skeletal muscle stem cells, lymphocytes and pancreatic islet cells.

The major factors that boost the growth of the cell therapy processing market are rise in the demand for chimeric antigen receptor (CAR) T cell therapy, increase in the incidence of cardiovascular diseases, rise in the R&D for the advancement in the research associated with cell therapy, rise in underst anding of the role of stem cells in inducing development of functional lung cells from both embryonic stem cells (ESCs) & induced pluripotent stem (iPS) cells, rise in the potential of cell therapies in the treatment of diseases associated with lungs using stem cell therapies, and an increase in a number of clinical studies relating to the development of cell therapy processing. In addition, increase in government investments for cell-based research, a rise in the adoption of regenerative drug, introduction of novel technologies for cell therapy processing, rise in the development of allogeneic cell therapy increase in number of GMP-certified production facilities, rise in the development of allogeneic cell therapy, and large number of oncology-oriented cell-based therapy clinical trials are expected to boost the cell therapy processing market growth during the forecast period. However, high-costs associated with the cell therapies, and bottlenecks experienced by manufacturers during commercialization of cell therapies are expected to hinder the growth of the market.

Based on offering type, the market is categorized into products, services, and software. Presently, products dominates the cell therapy processing market, and is anticipated to continue this trend over the forecast period. The key factors that driving the market growth are rise in the incidence of cardiovascular diseases, increase in demand for cell therapy processing, surge in adoption of allogeneic cell therapy, and introduction of novel technologies for cell therapy processing drives the market growth of this segment.

Based on application, the market is classified into cardiovascular devices, bone repair, neurological disorders, skeletal muscle repair, cancer, and others. At present, the skeletal muscle repair accounted for the majority of cell therapy processing market share owing to rise in incidence of skeletal muscle injury, rise in geriatric population, increase in The prevalence of chronic diseases, increase in usage of regenerative medicine, and an increase in adoption of minimally invasive surgeries drives the market growth of this segment.

According to Onkar Sumant, Manager, Healthcare, “The growth of the cell therapy processing market is attributed to increase in the incidence of cardiovascular diseases. Furthermore, rise in the demand for chimeric antigen receptor (CAR) t cell therapy, and an increase in the development of stem cell therapy approaches globe are the other factors that contribute to the growth of the cell therapy processing market.”

KEY FINDINGS OF THE STUDY
  • Based on offering type, the products segment held more than 82.32% share in the global market in 2018.
  • By application, the skeletal muscle repair segment accounted for the largest market share in 2018, and is expected to remain dominant throughout the forecast period.
  • Based on region, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 29.0% during the forecast period

North America accounted for approximately one-half of the global cell therapy processing market share in 2018 and is expected to remain dominant throughout the forecast period. This was attributed to increase in the popularity of stem cell research, rise in patient awareness towards stem cell therapies, and well developed healthcare infrastructure. On the other side, Asia-Pacific is expected to experience the highest growth rate during the forecast period majorly due to improvement in healthcare infrastructure, a rise in the number of hospitals equipped with advanced medical facilities, the developing R&D sector, rise in healthcare reforms, and technological advancements in the field of healthcare.
Note: Product cover images may vary from those shown
  • Cell Therapies Pty Ltd
  • Invitrx Inc.
  • Lonza Ltd
  • Merck & Co. Inc. (FloDesign Sonics)
  • NantWorks LLC
  • Neurogeneration Inc.
  • Novartis AG
  • Plasticell Ltd.
  • Regeneus Ltd
  • StemGenex Inc
Note: Product cover images may vary from those shown

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...